November 26, 2025 /

Webinar: Avidity Biosciences – EXPLORE44-OLE® Topline and Functional Data Presentation

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Avidity Biosciences joined PPMD for a community webinar on November 19, 2025, during which the company shared topline and functional data from their EXPLORE44-OLE® clinical trial. Avidity’s investigational therapy, delpacibart zotadirsen (abbreviated as del-zota), is in development for individuals with Duchenne muscular dystrophy who are amenable to exon 44 skipping.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo